Species Diversity of Candida from Hospital Environment in Plateau State, Nigeria
American Journal of Biomedical and Life Sciences
Volume 8, Issue 1, February 2020, Pages: 15-19
Received: Jan. 8, 2020; Accepted: Jan. 20, 2020; Published: Feb. 7, 2020
Views 28      Downloads 41
Authors
Nnadi Nnaemeka Emmanuel, Department of Microbiology, Faculty of Natural and Applied Sciences, Plateau State University, Bokkos, Nigeria
Miri Alexander Nanpyal, Department of Microbiology, Faculty of Natural and Applied Sciences, Plateau State University, Bokkos, Nigeria
Nanpon Kaduna, Department of Microbiology, Faculty of Natural and Applied Sciences, Plateau State University, Bokkos, Nigeria
Bege Jonathan, Environmental & Occupational Toxicology Unit, Department of Biochemistry, Faculty of Natural and Applied Sciences, Plateau State University, Bokkos, Nigeria
Iskender Karalti, Azerbaijan Medical University, Educational and Therapeutic Hospital, Central Laboratory, Baku, Azerbaijan; Yeditepe University, Faculty and Health Sciences, Department of Nutrition and Dietetics, İstanbul, Turkey
Article Tools
Follow on us
Abstract
In the past few years the role the hospital environment in the transmission of infections has increased leading to the increase in the incidence of morbidity and mortality associated with Candida infections. The hospital environment can serve as an alternative niche for the presence of opportunistic pathogens of public health concern. This study sought to use molecular approach to study the prevalence of Candida from hospital environments in Jos, Plateau State, Nigeria. Samples were collected from different hospital environments and cultured on Chromagar Candida media. Taqman PCR was then used to characterize the isolates, the ability of Candida to form biofilm was evaluated. In this study, Candida parapsilosis with 31.25% was the most prevalent Candida followed by Candida (Nakaseomyces) glabrata and Candida krusei with prevalence of 28.13%. The ability to form biofilms was evaluated for these environmental isolates, and it was observed that C. parapsilosis biofilm formation correlated with high prevalence with C. parapsilosis having high biofilm formation (20/64) followed by C. glabrata and C. krusei (18/64) each Environmental sampling has the potential to improve our knowledge about yeast biodiversity and the evolution of pathogenic yeasts with clinical relevance. This study is the first in Nigeria to study to characterize Candida from hospital environments in Jos, Plateau state Nigeria.
Keywords
Hospital Environments, Candida, Taqman PCR, Biofilm
To cite this article
Nnadi Nnaemeka Emmanuel, Miri Alexander Nanpyal, Nanpon Kaduna, Bege Jonathan, Iskender Karalti, Species Diversity of Candida from Hospital Environment in Plateau State, Nigeria, American Journal of Biomedical and Life Sciences. Vol. 8, No. 1, 2020, pp. 15-19. doi: 10.11648/j.ajbls.20200801.14
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
U. Binder, C. Lass-Flörl, Epidemiology of invasive fungal infections in the mediterranean area, Mediterranean journal of hematology and infectious diseases, 3 (2011).
[2]
R. Sabino, P. Sampaio, L. Rosado, Z. Videira, F. Grenouillet, C. Pais, Analysis of clinical and environmental Candida parapsilosis isolates by microsatellite genotyping—a tool for hospital infection surveillance, Clinical Microbiology and Infection, 21 (2015) 954. e951-954. e958.
[3]
S. Schelenz, F. Hagen, J. L. Rhodes, A. Abdolrasouli, A. Chowdhary, A. Hall, L. Ryan, J. Shackleton, R. Trimlett, J. F. Meis, First hospital outbreak of the globally emerging Candida auris in a European hospital, Antimicrobial Resistance & Infection Control, 5 (2016) 35.
[4]
A. Casadevall, D. P. Kontoyiannis, V. Robert, On the emergence of Candida auris: climate change, azoles, swamps and birds, bioRxiv, (2019) 657635.
[5]
S. Vallabhaneni, Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016, MMWR. Morbidity and mortality weekly report, 65 (2016).
[6]
S. R. Lockhart, K. A. Etienne, S. Vallabhaneni, J. Farooqi, A. Chowdhary, N. P. Govender, A. L. Colombo, B. Calvo, C. A. Cuomo, C. A. Desjardins, E. L. Berkow, M. Castanheira, R. E. Magobo, K. Jabeen, R. J. Asghar, J. F. Meis, B. Jackson, T. Chiller, A. P. Litvintseva, Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses, Clin Infect Dis, 64 (2017) 134-140.
[7]
D. Delfino, F. Scordino, I. Pernice, C. L. Passo, R. Galbo, A. David, I. Barberi, G. Criseo, A. Cascio, O. Romeo, Potential association of specific Candida parapsilosis genotypes, bloodstream infections and colonization of health workers' hands, Clinical Microbiology and Infection, 20 (2014) O946-O951.
[8]
C. Savastano, E. de Oliveira Silva, L. L. Gonçalves, J. M. Nery, N. C. Silva, A. L. T. Dias, Candida glabrata among Candida spp. from environmental health practitioners of a Brazilian Hospital, brazilian journal of microbiology, 47 (2016) 367-372.
[9]
D. A. Opulente, Q. K. Langdon, K. V. Buh, M. A. Haase, K. Sylvester, R. V. Moriarty, M. Jarzyna, S. L. Considine, R. M. Schneider, C. T. Hittinger, Pathogenic budding yeasts isolated outside of clinical settings, FEMS yeast research, 19 (2019).
[10]
F. Morio, Dear medical mycologists, it is time to look outside the box, FEMS yeast research, (2019).
[11]
L. J. Douglas, Candida biofilms and their role in infection, Trends in microbiology, 11 (2003) 30-36.
[12]
M. S. Rangel-Frausto, T. Wiblin, H. M. Blumberg, L. Saiman, J. Patterson, M. Rinaldi, M. Pfaller, J. E. Edwards Jr, W. Jarvis, J. Dawson, National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units, Clinical Infectious Diseases, 29 (1999) 253-258.
[13]
M. Branchini, M. Pfaller, J. Rhine-Chalberg, T. Frempong, H. Isenberg, Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis, Journal of clinical microbiology, 32 (1994) 452-456.
[14]
J. H. Shin, S. J. Kee, M. G. Shin, S. H. Kim, D. H. Shin, S. K. Lee, S. P. Suh, D. W. Ryang, Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources, Journal of Clinical Microbiology, 40 (2002) 1244-1248.
[15]
H. Badali, S. Rezaie, J. F. Meis, S. A. K. Afshari, M. Modiri, F. Hagen, M. Moazeni, R. Mohammadi, S. Khodavaisy, Microsatellite genotyping of clinical Candida parapsilosis isolates, Current medical mycology, 3 (2017) 15.
[16]
R. A. Cordeiro, R. S. Brilhante, L. D. Pantoja, R. E. Moreira Filho, P. R. Vieira, M. F. Rocha, A. J. Monteiro, J. J. Sidrim, Isolation of pathogenic yeasts in the air from hospital environments in the city of Fortaleza, northeast Brazil, The Brazilian Journal of Infectious Diseases, 14 (2010) 30-34.
[17]
L. R. Storti, G. Pasquale, R. Scomparim, A. L. Galastri, F. Alterthum, W. Gambale, C. R. Paula, Candida spp. isolated from inpatients, the environment, and health practitioners in the Pediatric Unit at the Universitary Hospital of the Jundiaí Medical College, State of São Paulo, Brazil, Revista da Sociedade Brasileira de Medicina Tropical, 45 (2012) 225-231.
[18]
O. Romeo, D. Delfino, A. Cascio, C. L. Passo, M. Amorini, D. Romeo, I. Pernice, Microsatellite-based genotyping of Candida parapsilosis sensu stricto isolates reveals dominance and persistence of a particular epidemiological clone among neonatal intensive care unit patients, Infection, Genetics and Evolution, 13 (2013) 105-108.
[19]
M. Pfaller, D. Diekema, Epidemiology of invasive candidiasis: a persistent public health problem, Clinical microbiology reviews, 20 (2007) 133-163.
[20]
F. Lamoth, S. R. Lockhart, E. L. Berkow, T. Calandra, Changes in the epidemiological landscape of invasive candidiasis, Journal of Antimicrobial Chemotherapy, 73 (2018) i4-i13.
[21]
E. Matsumoto, L. Boyken, S. Tendolkar, J. McDanel, M. Castanheira, M. Pfaller, D. Diekema, Candidemia surveillance in Iowa: emergence of echinocandin resistance, Diagnostic microbiology and infectious disease, 79 (2014) 205-208.
[22]
A. A. Cleveland, L. H. Harrison, M. M. Farley, R. Hollick, B. Stein, T. M. Chiller, S. R. Lockhart, B. J. Park, Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance, PLoS One, 10 (2015) e0120452.
[23]
N. P. Govender, J. Patel, R. E. Magobo, S. Naicker, J. Wadula, A. Whitelaw, Y. Coovadia, R. Kularatne, C. Govind, S. R. Lockhart, Emergence of azole-resistant Candida parapsilosis causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa, Journal of Antimicrobial Chemotherapy, 71 (2016) 1994-2004.
[24]
P. Pronovost, D. Needham, S. Berenholtz, D. Sinopoli, H. Chu, S. Cosgrove, B. Sexton, R. Hyzy, R. Welsh, G. Roth, An intervention to decrease catheter-related bloodstream infections in the ICU, New England Journal of Medicine, 355 (2006) 2725-2732.
[25]
V. Hallur, A. Mahapatra, B. Deb, S. Tripathy, S. Misra, A. Praharaj, Comparison of virulence profile of C. albicans and C. tropicalis isolated from patients with Candida infection and hospital environment, MEDICAL MYCOLOGY, OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND, 2018, pp. S152-S152.
[26]
M. Quirós, P. Martorell, M.-J. Valderrama, A. Querol, J. M. Peinado, M.-I. de Silóniz, PCR-RFLP analysis of the IGS region of rDNA: a useful tool for the practical discrimination between species of the genus Debaryomyces, Antonie van Leeuwenhoek, 90 (2006) 211-219.
[27]
D. Wagner, A. Sander, H. Bertz, J. Finke, W. Kern, Breakthrough invasive infection due to Debaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis, Infection, 33 (2005) 397-400.
[28]
D. Diekema, S. Messer, A. Brueggemann, S. Coffman, G. Doern, L. Herwaldt, M. Pfaller, Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study, Journal of Clinical Microbiology, 40 (2002) 1298-1302.
[29]
M. Desnos-Ollivier, M. Ragon, V. Robert, D. Raoux, J.-C. Gantier, F. Dromer, Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii), Journal of clinical microbiology, 46 (2008) 3237-3242.
[30]
B. Almirante, D. Rodríguez, B. J. Park, M. Cuenca-Estrella, A. M. Planes, M. Almela, J. Mensa, F. Sanchez, J. Ayats, M. Gimenez, Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003, Journal of Clinical Microbiology, 43 (2005) 1829-1835.
[31]
G. T. Cole, A. A. Halawa, E. J. Anaissie, The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside, Clinical Infectious Diseases, 22 (1996) S73-S88.
[32]
J. H. Rex, J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. Van Der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia, New England Journal of Medicine, 331 (1994) 1325-1330.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186